advertisement
Abstract #23480 Published in IGR 11-2
Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: Systematic review
Martinez-Carpio PA; Bonafonte-Marquez E; Heredia-Garcia CD; Bonafonte-Royo SArchivos de la Sociedad Española de Oftalmologia 2008; 83: 579-587
PURPOSE: Systematic review on efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of neovascular glaucoma (NVG). All original papers published in Medline (prior to August 2008) were included. METHODS: Search and selection of information on the internet and in Medline, validated by Kappa Index (K). Statistical and clinical study of the results in the selected articles on a one by one basis. RESULTS: 26 original papers analyzed the efficacy and safety of the procedure in case reports and short series of cases (127 eyes). The efficacy calculated in the sample was 68.7% and the recurrence rate was 18.6% in 4.2 months of follow-up. All studies were after 2006 and none of them was a clinical randomized controlled assay. Ophthalmic complications were under 0.78% and no systemic complications were found. CONCLUSIONS: The use of bevacizumab demonstrates that intravitreal injections may be effective and useful to manipulate growth factors in the anterior chamber. IVB could serve as a first line treatment for NVG. Clinical trials are needed to confirm these results before its use is authorized. LA: Spanish
P. A. Martinez-Carpio. IMC-Investilaser, C/. Sarret, 13, 08205 Sabadell (Barcelona), Spain. pmc@investilaser.com
Classification:
9.4.5.1 Neovascular glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous)
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)
